Kurs & Likviditet
Kalender
| 2025-02-21 | Bokslutskommuniké 2024 |
| 2024-11-15 | Kvartalsrapport 2024-Q3 |
| 2024-08-23 | Kvartalsrapport 2024-Q2 |
| 2024-06-28 | Årsstämma 2024 |
| 2024-05-17 | Kvartalsrapport 2024-Q1 |
| 2024-05-17 | Ordinarie utdelning CLS B 0.00 SEK |
| 2024-04-12 | Extra Bolagsstämma 2024 |
| 2024-02-23 | Bokslutskommuniké 2023 |
| 2023-11-17 | Kvartalsrapport 2023-Q3 |
| 2023-08-25 | Kvartalsrapport 2023-Q2 |
| 2023-06-29 | Årsstämma 2023 |
| 2023-06-22 | Ordinarie utdelning CLS B 0.00 SEK |
| 2023-06-08 | Extra Bolagsstämma 2023 |
| 2023-05-25 | Kvartalsrapport 2023-Q1 |
| 2023-02-23 | Bokslutskommuniké 2022 |
| 2022-11-22 | Extra Bolagsstämma 2022 |
| 2022-11-17 | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | Kvartalsrapport 2022-Q2 |
| 2022-06-29 | Ordinarie utdelning CLS B 0.00 SEK |
| 2022-06-28 | Årsstämma 2022 |
| 2022-05-19 | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | Bokslutskommuniké 2021 |
| 2021-11-18 | Kvartalsrapport 2021-Q3 |
| 2021-08-24 | Kvartalsrapport 2021-Q2 |
| 2021-06-29 | Ordinarie utdelning CLS B 0.00 SEK |
| 2021-06-28 | Årsstämma 2021 |
| 2021-05-19 | Kvartalsrapport 2021-Q1 |
| 2021-03-31 | Extra Bolagsstämma 2021 |
| 2021-02-26 | Bokslutskommuniké 2020 |
| 2020-11-19 | Kvartalsrapport 2020-Q3 |
| 2020-08-26 | Kvartalsrapport 2020-Q2 |
| 2020-06-12 | Ordinarie utdelning CLS B 0.00 SEK |
| 2020-06-11 | Årsstämma 2020 |
| 2020-05-28 | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | Bokslutskommuniké 2019 |
| 2019-11-21 | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | Kvartalsrapport 2019-Q2 |
| 2019-06-12 | Ordinarie utdelning CLS B 0.00 SEK |
| 2019-05-17 | Årsstämma 2019 |
| 2019-05-16 | Kvartalsrapport 2019-Q1 |
| 2019-03-18 | Extra Bolagsstämma 2019 |
| 2019-02-14 | Bokslutskommuniké 2018 |
| 2018-11-22 | Kvartalsrapport 2018-Q3 |
| 2018-08-23 | Kvartalsrapport 2018-Q2 |
| 2018-06-20 | Årsstämma 2018 |
| 2018-06-14 | Ordinarie utdelning CLS B 0.00 SEK |
| 2018-05-24 | Kvartalsrapport 2018-Q1 |
| 2018-05-18 | Extra Bolagsstämma 2018 |
| 2018-02-22 | Bokslutskommuniké 2017 |
| 2017-11-16 | Kvartalsrapport 2017-Q3 |
| 2017-07-17 | Kvartalsrapport 2017-Q2 |
| 2017-06-28 | Ordinarie utdelning CLS B 0.00 SEK |
| 2017-06-27 | Årsstämma 2017 |
| 2017-05-18 | Kvartalsrapport 2017-Q1 |
| 2017-01-31 | Bokslutskommuniké 2016 |
| 2017-01-20 | Extra Bolagsstämma 2017 |
| 2016-11-17 | Kvartalsrapport 2016-Q3 |
| 2016-08-18 | Kvartalsrapport 2016-Q2 |
| 2016-06-16 | Årsstämma 2016 |
| 2016-05-19 | Kvartalsrapport 2016-Q1 |
| 2016-02-21 | Bokslutskommuniké 2015 |
| 2015-11-19 | Kvartalsrapport 2015-Q3 |
| 2015-08-20 | Kvartalsrapport 2015-Q2 |
| 2015-06-12 | Ordinarie utdelning CLS B 0.00 SEK |
| 2015-06-11 | Årsstämma 2015 |
| 2015-05-21 | Kvartalsrapport 2015-Q1 |
| 2015-02-23 | Bokslutskommuniké 2014 |
| 2014-11-14 | Kvartalsrapport 2014-Q3 |
| 2014-08-20 | Kvartalsrapport 2014-Q2 |
| 2014-06-18 | Ordinarie utdelning CLS B 0.00 SEK |
| 2014-06-17 | Årsstämma 2014 |
| 2014-05-22 | Kvartalsrapport 2014-Q1 |
| 2014-02-24 | Bokslutskommuniké 2013 |
| 2013-11-22 | Kvartalsrapport 2013-Q3 |
| 2013-09-19 | Extra Bolagsstämma 2013 |
| 2013-08-20 | Kvartalsrapport 2013-Q2 |
| 2013-06-10 | Ordinarie utdelning CLS B 0.00 SEK |
| 2013-06-07 | Årsstämma 2013 |
| 2013-05-24 | Kvartalsrapport 2013-Q1 |
| 2013-02-25 | Bokslutskommuniké 2012 |
| 2012-11-23 | Kvartalsrapport 2012-Q3 |
| 2012-08-24 | Kvartalsrapport 2012-Q2 |
| 2012-06-08 | Ordinarie utdelning CLS B 0.00 SEK |
| 2012-06-07 | Årsstämma 2012 |
| 2012-04-20 | Kvartalsrapport 2012-Q1 |
| 2012-01-09 | Bokslutskommuniké 2011 |
| 2012-01-04 | Extra Bolagsstämma 2012 |
| 2011-11-21 | Kvartalsrapport 2011-Q3 |
| 2011-09-26 | Kapitalmarknadsdag 2010 |
| 2011-08-22 | Kvartalsrapport 2011-Q2 |
| 2011-06-10 | Årsstämma 2011 |
| 2011-05-20 | Kvartalsrapport 2011-Q1 |
| 2011-02-24 | Bokslutskommuniké 2010 |
| 2010-11-24 | Kvartalsrapport 2010-Q3 |
| 2010-08-25 | Kvartalsrapport 2010-Q2 |
| 2010-05-28 | Ordinarie utdelning CLS B 0.00 SEK |
| 2010-05-26 | Kvartalsrapport 2010-Q1 |
| 2010-02-26 | Bokslutskommuniké 2009 |
| 2009-11-30 | Kvartalsrapport 2009-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
NEWPORT BEACH, Calif., Oct. 07, 2022 (GLOBE NEWSWIRE) -- CLS Americas, a subsidiary of Clinical Laserthermia Systems AB, today announced it will exhibit its TRANBERG™ Thermal Therapy System at the Unio Health Partners Summit being held October 6-8, 2022 at the Renaissance Newport Beach Hotel, Newport, CA. The TRANBERG™ System is designed to provide precise and accurate prostate tumor ablation in a minimally invasive, outpatient setting. Compared to other focal therapies, focal laser ablation has demonstrated higher levels of precision and accuracy with lower risk of side effects, such as erectile dysfunction and urinary incontinence.
“We’re excited to introduce our office-based TRANBERG focal laser ablation system to the urologists and providers at the Unio Health Partners Summit,” said Michael Magnani, president of CLS Americas. “Unio provides best-in-class clinical programs and ancillary services to its affiliates. It’s a great opportunity for us to partner with them for the summit.”
TRANBERG™ Thermal Therapy System
The TRANBERG™ Thermal Therapy System can be configured for MR/US fusion-guided procedures using real-time tissue temperature measurements for precise therapy and ablation control. It includes a desk-top mobile laser unit, innovative non-cooled laser applicators, tissue temperature probes, and procedure-specific accessories. The TRANBERG system can be deployed in either a transperineal or transrectal approach.
About CLS and the TRANBERG® Product Portfolio
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG® Thermal Therapy Systems, including ThermoguideTM Workstation and sterile disposables, for minimally invasive laser ablation of soft tissue, cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. CLS aims at expanding the current approvals to also include treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal treatment effect. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.
For more information about CLS, please visit the Company's website for the US market: www.clinicallaser.com/en.